- Home
- LVLU vs ANTX Comparison
LVLU vs ANTX Comparison
Compare LVLU & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- ANTX
- Stock Information
- Founded
- LVLU 1996
- ANTX 2017
- Country
- LVLU United States
- ANTX United States
- Employees
- LVLU N/A
- ANTX N/A
- Industry
- LVLU Catalog/Specialty Distribution
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- ANTX Health Care
- Exchange
- LVLU Nasdaq
- ANTX Nasdaq
- Market Cap
- LVLU 36.0M
- ANTX 37.6M
- IPO Year
- LVLU 2021
- ANTX 2022
- Fundamental
- Price
- LVLU $0.83
- ANTX $1.13
- Analyst Decision
- LVLU Hold
- ANTX Hold
- Analyst Count
- LVLU 3
- ANTX 5
- Target Price
- LVLU $1.58
- ANTX $3.50
- AVG Volume (30 Days)
- LVLU 23.5K
- ANTX 149.8K
- Earning Date
- LVLU 03-05-2025
- ANTX 03-27-2025
- Dividend Yield
- LVLU N/A
- ANTX N/A
- EPS Growth
- LVLU N/A
- ANTX N/A
- EPS
- LVLU N/A
- ANTX N/A
- Revenue
- LVLU $324,699,000.00
- ANTX N/A
- Revenue This Year
- LVLU N/A
- ANTX N/A
- Revenue Next Year
- LVLU $1.72
- ANTX N/A
- P/E Ratio
- LVLU N/A
- ANTX N/A
- Revenue Growth
- LVLU N/A
- ANTX N/A
- 52 Week Low
- LVLU $0.75
- ANTX $0.87
- 52 Week High
- LVLU $2.13
- ANTX $3.88
- Technical
- Relative Strength Index (RSI)
- LVLU 38.00
- ANTX 44.20
- Support Level
- LVLU $0.81
- ANTX $1.09
- Resistance Level
- LVLU $0.85
- ANTX $1.20
- Average True Range (ATR)
- LVLU 0.07
- ANTX 0.05
- MACD
- LVLU 0.01
- ANTX 0.01
- Stochastic Oscillator
- LVLU 34.43
- ANTX 52.98
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.